PsyBio Therapeutics (STU:PSYB) Gross Margin %: 0.00% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PsyBio Therapeutics Gross Margin %?

PsyBio Therapeutics STU:PSYB Gross Margin % is 0.00% as of Jun. 2023.

Gross Margin % is calculated as gross profit divided by its revenue. PsyBio Therapeutics's Gross Profit for the three months ended in Jun. 2023 was €-0.02 Mil. PsyBio Therapeutics's Revenue for the three months ended in Jun. 2023 was €0.00 Mil. Therefore, PsyBio Therapeutics's Gross Margin % for the quarter that ended in Jun. 2023 was 0.00%.


The historical rank and industry rank for PsyBio Therapeutics's Gross Margin % or its related term are showing as below:


STU:PSYB's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.905
* Ranked among companies with meaningful Gross Margin % only.

PsyBio Therapeutics had a gross margin of % for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for PsyBio Therapeutics was 0.00% per year.

PsyBio Therapeutics  (STU:PSYB) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PsyBio Therapeutics had a gross margin of % for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

PsyBio Therapeutics Gross Margin % Related Terms

PsyBio Therapeutics Gross Margin % Historical Data

* Premium members only.

The historical data trend for PsyBio Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyBio Therapeutics Gross Margin % Chart

PsyBio Therapeutics Annual Data
Trend Dec21 Dec22
Gross Margin %
0.00 0.00

PsyBio Therapeutics Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:PSYB vs VRTX, REGN, SGEN: Gross Margin % Comparison

For the Biotechnology subindustry, PsyBio Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PsyBio Therapeutics Gross Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PsyBio Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where PsyBio Therapeutics's Gross Margin % falls into.


PsyBio Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

PsyBio Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0.047) / 0
= %

PsyBio Therapeutics's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0.023) / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
PsyBio Therapeutics (STU:PSYB) has a Gross Margin % of 0.00% as of Jun. 2023. Gross margin is the ratio of total gross profit to net sales. View historical data on PsyBio Therapeutics and its competitors.
Is PsyBio Therapeutics' Gross Margin % too high?
PsyBio Therapeutics' current Gross Margin % is 0.00%.
How does PsyBio Therapeutics' Gross Margin % compare to VRTX and REGN?
PsyBio Therapeutics' Gross Margin % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PsyBio Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PsyBio Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyBio Therapeutics stock overvalued right now?
PsyBio Therapeutics (STU:PSYB) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PsyBio Therapeutics (STU:PSYB), the current Gross Margin % is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyBio Therapeutics Business Description

Address 1624 Washington Street, Denver, CO, USA, 80203
PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.